Doxoves¢â - Liposomal Doxorubicin HCl, New 2mg/mL
Ç×Á¾¾ç Ȱ¼ºÀ» °®´Â Ç×»ý¹°Áú Doxorubicin HClÀ» ³»Æ÷ÇÑ liposomeÀÔ´Ï´Ù. Doxorubicin HClÀ» liposome ³»¿¡ ³»Æ÷
½ÃÅ´À¸·Î½á pharmacokinetics/pharmacodynamics(PK/PD)ÀûÀÎ ÀÛ¿ëÀÌ °³¼±µË´Ï´Ù.
ÀÔ°æÀÌ ±ÕÀÏÇϱ⠶§¹®¿¡ lot °£ÀÇ Â÷À̰¡ ÀûÀº °íǰÁú·Î¼, ³ôÀº ºÀÀÔ È¿À²À» º¸À̵µ·Ï Á¶Á¦µÇ¾î ÀÖ½À´Ï´Ù.
Doxorubicin HClÀÌ ¾ø´Â control¿ë liposomeµµ ÀÖ½À´Ï´Ù.
* DoxorubicinÀº, reverse transcriptase, RNA polymeraseÀÇ È°¼ºÀ» ¾ïÁ¦ÇÏ´Â Ç×»ý¹°ÁúÀÔ´Ï´Ù. Intercalation¿¡
ÀÇÇØ ÀÌÁß °¡´Ú DNA¿¡ °áÇÕÇÏ¿©, DNAÀÇ º¹Á¦¡¤Àü»ç¸¦ ¾ïÁ¦ÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ°í ÀÖÀ¸¸ç, ¼¼Æ÷ »ç¸êÀ» À¯µµÇÕ´Ï´Ù.

Cryo-EM of FormuMax's liposome doxorubicin HCl (F30204B-D) (Image taken by NanoImaging Services Inc.)
FormuMax has been providing custom-made formulations of liposomal doxorubicin HCl with various lipid
compositions and particle sizes. There has been an increased demand of liposomal doxorubicin
comparable to the commercial Doxil¢ç. Now we are proudly naming our product, Doxoves¢ç, and making it
available to you at an affordable price.
Doxoves¢çis manufactured to high quality with consistent lot-lot characteristics, tight particle size distribution
and high drug encapsulation efficiency. A high drug concentration of 4.0 mg/mL (40mM lipid) allows
researchers to perform experiments athigher concentrations/doses.
Doxoves¢ç is comparable to the
commercial product Doxil¢ç in characteristics, stability and pharmacokinetics. Cryo-TEM studies have
shown that the encapsulated doxorubicin forms the same type of rod-like structures as in Doxil¢ç. A recent
PK study of two batches of Doxoves¢ç demonstrated an excellent PK profile with t1/2 of 30-40hr similar to that
of Doxil¢ç.